Posted by Michael Wonder on 17 Feb 2022
FDA grants fast track designation to SBT101, the first investigational AAV based gene therapy for patients with adrenomyeloneuropathy
16 February 2022 - Initiation of Phase 1/2 clinical trial expected in the second half of 2022.
SwanBio Therapeutics today announced that the U.S. FDA has granted fast track designation to its lead candidate, SBT101, for the treatment of adrenomyeloneuropathy.
